| Literature DB >> 28974019 |
Katayoon Kalantari1,2, Mona Moniri3, Amin Boroumand Moghaddam4, Raha Abdul Rahim5, Arbakariya Bin Ariff6,7, Zahra Izadiyan8, Rosfarizan Mohamad9,10.
Abstract
Zerumbone (ZER) is a phytochemical isolated from the subtropical Zingiberaceae family and as a natural compound it has different biomedical properties such as antioxidant, anti-inflammatory anti-proliferative activity. ZER also has effects on angiogenesis and acts as an antitumor drug in the treatment of cancer, showing selective toxicity toward various cancer cell lines. Several techniques also have been established for extraction of ZER from the rhizomes of ginger. This review paper is an overview of recent research about different extraction methods and their efficiencies, in vivo and vitro investigations of ZER and also its prominent chemopreventive properties and treatment mechanisms. Most of the studies mentioned in this review paper may be useful use as a knowledge summary to explain ZER extraction and anticancer activities, which will show a way for the development of strategies in the treatment of malignancies using ZER.Entities:
Keywords: anticancer properties; antimicrobial; antioxidant; extraction methods; zerumbone
Mesh:
Substances:
Year: 2017 PMID: 28974019 PMCID: PMC6151537 DOI: 10.3390/molecules22101645
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of ZER [28].
Figure 2Different methods of ZER extraction.
Figure 3Separation process in solvent extraction.
Figure 4Supercritical fluid extraction using CO2.
Figure 5Soxhlet schematic.
In vitro biological effects of ZER.
| Organ | Cell Line | Biological Effects of ZER | References |
|---|---|---|---|
| Pancreatic | INS-1 rat pancreatic b cells | Enhances the viability of INS-1 b cells (high glucose). ZER can attenuate significantly the apoptosis of high glucose-induced INS-1 cells. | [ |
| Human pancreatic carcinoma (PaCa) | Excellent inhibitor of Jak2/Stat3, which inhibits the growing of promigratory gene as well as the expression and migration of cancer cells. | [ | |
| Human pancreatic carcinoma (PANC-1 and SW1990) | Effect on cell viability inhibition and induces apoptosis in time-dependent manner. | [ | |
| Human pancreatic carcinoma (PaCa) | By inhibition of NF-1D705B and NF-κB-dependent proangiogenic gene products, ZER can inhibit PaCa-associated angiogenesis. | [ | |
| Lung | ATCC-HTB-57 cells | Some novel compounds fabricated through azazerumbone conjugation with 2,4-dihydroxychalcones. These compounds showed anti-proliferative activity against the LU-1, Hep-G2, MCF-7 and SW480 human cancer cell lines. | [ |
| TGF-β1-stimulated human (A549) cells | Demonstrates the anti-EMT and anti-metastatic properties of zerumbone in A549 lung cancer cells under TGF-β1-stimulation. | [ | |
| Human small cell lung carcinoma (NCI-H187) | Inhibits the HSP 27 protein as a monomeric form of. Derivative of ZER induces strong cytotoxicity. | [ | |
| Human non-small cell lung cancer (NSCLC) cells | The viability of NSCLC cells, significantly impaired by treatments of in a dose-dependent manner and NSCLC. | [ | |
| Liver | ATCC-HTB-22 cells | Some novel compounds fabricated through azazerumbone conjugation with 2,4-dihydroxychalcones. These compounds showed anti-proliferative activity against the LU-1, Hep-G2, MCF-7 and SW480 human cancer cell lines. | [ |
| HepG2 cells | Some novel compounds fabricated through azazerumbone conjugation with 2,4-dihydroxychalcones. These compounds showed anti-proliferative activity against the LU-1, Hep-G2, MCF-7 and SW480 human cancer cell lines. | [ | |
| Murine hepatoma cells (Hepa1c1c7) | Increases proteasome activity, p62 and microtubule-associated protein 1 light-chain 3 (LC3)-II. | [ | |
| Breast | ATCC-HTB-22 cells | The conjugation of azazerumbone and 2,4-dihydroxychalcones use for the preparation of novel target compounds. The anti-proliferative activity of these compounds against the LU-1, Hep-G2, MCF-7 and SW480 human cancer cell lines improves compared to azazerumbone or ZER. | [ |
| MDA-MB-231, MCF-7, SUM159 cells | Exposure of cells to ZER resultes in increased cleavage of Notch2 in each cell line.Notch2 activation by ZER inhibits its proapoptotic and anti-migratory response. | [ | |
| kinase κB (IKKβ) and the Nuclear factor κB (NF-κB) component proteins | Inhibits the IKKβ kinase that activates the NF-κB and also binds to the NF-κB complex in the TNF pathway. Blocking both proteins can lead to inhibition of cell proliferating proteins to be downregulated and possibly ultimate induction of apoptosis. | ||
| Human mammary gland adenocarcinoma (MDA-MB-231) cell line | Suppresses the proliferation of MDA-MB-231 cells. | [ | |
| Hs578T and MDA-MB231 cells | IL-1β-induced IL-8 and MMP-3 expression, migration and invasion decrease. | ||
| MCF-7 and MDAMB-231 human cells | Induces significant expression of DR4. | [ | |
| Human mammary adenocarcinoma MDA-MB-231 Cell Line | ZER and ZER-NLC markedly suppressed the proliferation ofMDA-MB-231 cells. | [ | |
| SKBR3 breast cancer cells | ZER downregulated the level of CD44 expression in CD44+. The induction of CD44 expression by EGFR ligands, EGF or TGF-α, was significantly decreased by ZER treatment. | [ | |
| Leukemia | MDA-MB-231Cell Line | Proliferation of MDA-MB significantly suppressed by ZER. | [ |
| CML-K562 cells | Inhibits K562 cell proliferation and colony formation capability. | [ | |
| WEHI-3B cells | The growth of leukemia cells inhibits. | [ | |
| Human myeloid leukemia (HL60) | Drops off the percentage of HL60 cell viability. | [ | |
| T-acute lymphoblastic leukemia, CEM-ss cells | Cytotoxic influence on CEM-ss cells and able to apoptosis the T-acute lymphoblastic leukemia. | [ | |
| Human T-cell acute lymphoblastic leukemia (Jurkat) cells | Used as a system with sustained-release drug carrier mechanism. ZER activated the caspase-3 and caspase-9 and induced intrinsic apoptotic pathway, cytochrome c release from mitochondria, and PARP cleavage. | [ | |
| Human peripheral blood lymphocytes (PBL) | The overall clastogenic effect not significant and is a cytotoxic but not a clastogenic substance in human PBL. | [ | |
| Mice thymocytes and splenocytes human PBMC | Proliferation in stimulates time- and dose-dependent manner of human PBMC and mice cells upregulates human cytokine immunomodulatory. | [ | |
| Human peripheral blood lymphocytes | At high concentrations induces an apparent substantial increase in the micronuclei frequency. | [ | |
| Colon | Cells of mice thymocytes, mice splenocytes and human human peripheral blood mononuclear | ZEr activated the mice thymocytes, splenocytes and PBMC with dosage dependent manne. | [ |
| Colorectal cancer cells, (CRC) cells | ZER enhanced radiation-induced cell cycle arrest (G2/M), increased radiation-induced apoptosis and enhanced radiation-induced DNA damage. | [ | |
| Prostate | Hormone refractory prostate cancer (HRPC) cell lines | Induces antiproliferative and apoptotic influence on PC-3 and DU-145, 2 human hormonerefractory prostate cancer (HRPC) cell lines. | [ |
| Brain | Human meningioma cell lines (IOMM-Lee, CH157MN) | Induces apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 β (GSK3β) via inhibition of the Wnt5/β-catenin pathway. | |
| Human brain malignant glioma (GBM8401) | GBM8401 cells death induction with a dose-dependent pattern. | [ | |
| Human brain malignant glioma (U87MG) | Transfection of GBM 8401 cells with WT IKKα inhibite ZER-induced apoptosis, and ZER markedly decreases IKKα phosphorylation levels with a time-dependent pattern. | [ | |
| Kidney | Human RCC cell line 786-O | Suppresses STAT3 activation with a dose- and time-dependent pattern in RCC cells. | [ |
| Normal African green monkey kidney cells | Nonsignificant cytotoxicity with 30 µM IC50. | [ | |
| Ovarian | Normal Chinese hamster ovary cells (CHO) | Has genotoxic produces and cytotoxic influences in high concentrations. | [ |
| Miscellaneous | human umbilical vein endothelial cells (HUVECs) | Inhibits HUVECs proliferation, migration and tubule formation. | [ |
| Human oral cancer (KB) | ZER derivatives induces strong cytotoxicity. | [ | |
| Gastric | Umbilical vein endothelial cells (HUVECs) | Proliferation of cell, VEGF expression and NF-κB activity in AGS cells inhibited by ZER. Reduction in both VEGF expression and NF-κB activity in AGS cells. | [ |
| Human gastric adenocarcinoma (AGS) | Inhibits tumor angiogenesis via reduction of VEGF production and NF-κB activity. | [ | |
| Skin | Murine epidermal cells (JB6 Cl41) | Murine epidermal cells (JB6 Cl41) Induces heme oxygenase-1 expression by activation of Nrf2. | [ |
In vivo biological effects of ZER.
| Organ | Animal Model | ZER Route | Biological Effects of ZER | References |
|---|---|---|---|---|
| Lung | BALB/c female mice | Intraperitoneal injection | Effectively controls the growth of tumor and metastasis via delayed progression cancer cell cycle and apoptosis. | [ |
| Kidney | Adult male Sprague Dawley rats | Injected intra articularly | Significantly induction in cytosolic glutathione-S-transferase enzyme activity. | [ |
| Six-week-old athymic nu/nu female mice | Injection | STAT3 activation is inhibited in tissues of tumor and the human RCC xenograft tumors growth. | [ | |
| Leukemia | Male BALB/c mice | Intraperitoneal injection | The growth of leukemia cells inhibits. | [ |
| Chinese Hamster Ovary (CHO) cells and rat bone marrow polychromatic erythrocytes (PCEs) | Intraperitoneal injection | The leukemia cells number in the spleen of BALB/c leukemia mice markedly decreases after 28 days of orally treatment with different doses of ZER-NLC. Inhibits cell proliferation and causes cytotoxicity in the rat bone marrow. | [ | |
| Miscellaneous | 28-Days-old C57BL/6 male mice | Intraperitoneal injection | Significant decreases in content of vascularization and hemoglobin in the plugs from ZER-treated mice, than control mice. | [ |
| Syrian golden hamsters | Oral dose | Decreases hepatic mRNA levels of sterol regulatory element-binding protein-1c and its lipogenic target genes, included fatty acid synthase, acetyl-CoA carboxylase 1, and stearoyl-CoA desaturase 1. | [ | |
| Male Sprague Dawley rats | Intraperitoneal injection | Increase with dose-dependent manner in MN production. No significant effect on human PBL by the overall clastogenic. | [ | |
| Male Wistar rats | Oral dose | Decreases infiltration of macrophages, IL-1, IL-6, and TNF-α produced by p38 mitogen-activated protein kinase activation. | [ | |
| Breast | Female severe combined immune deficient (SCID) mouse | Intraperitoneal injection | Retards growth of orthotopic MDA-MB-231 xenografts in association with induction in apoptosis and suppression of cell proliferation (Ki-67 expression). | [ |
| 4T1 challenged mice | Oral feeding | ZER controlled the growth of tumor and metastasis by delaying the cancer cell cycle progression and apoptosis. | [ | |
| Skin | Female HR-1 hairless mice | Topical application | increases of Nrf2 nuclear translocation followed by the promoter activity of HO-1, and also enhances Nrf2 direct binding to the antioxidant response element. | [ |
| Liver | Male Sprague Dawley rats | Oral dose | Upregulates heat shock protein expressions in the liver Confers thermoresistant phenotype. | [ |
| Male golden Syrian Hamsters | Oral dose | Improves dyslipidemia by modulating the genes expression involved in the lipolytic and lipogenic pathways of lipids metabolism | [ | |
| Colon | Pathogen-free male Sprague–Dawley rats | Intraperitoneal injection | Lowers expression of PCNA is observed in the rat liver | [ |
| Paw | Mice | Intraperitoneal injection | Significantly inhibited the production of paw edema induced by carrageenan in dose-dependent. | [ |
| Eye | Female imprinting control region (ICR) mice | Oral dose | Inhibits the expressions of NF-κB, iNOS, and TNF-α. Abrogates nuclear translocation of NF-κB. | [ |
Figure 6Proposed signaling pathways of ZER-induced apoptosis in cancerous cells (A); The cytotoxicity effects of ZER on leukemia cells through cell cycle arrest (B).
Figure 7Different approaches of ZER can effect on liver cancer cells.